Industry
Biotechnology
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Loading...
Open
127.34
Mkt cap
7.3B
Volume
399K
High
127.34
P/E Ratio
-15.54
52-wk high
161.00
Low
120.77
Div yield
N/A
52-wk low
90.13
Portfolio Pulse from Benzinga Insights
April 18, 2024 | 7:30 pm
Portfolio Pulse from Benzinga Newsdesk
April 18, 2024 | 1:43 pm
Portfolio Pulse from Benzinga Insights
April 03, 2024 | 5:00 pm
Portfolio Pulse from Benzinga Newsdesk
April 02, 2024 | 2:47 pm
Portfolio Pulse from Benzinga Newsdesk
April 01, 2024 | 12:35 pm
Portfolio Pulse from Benzinga Newsdesk
March 15, 2024 | 12:41 pm
Portfolio Pulse from Benzinga Insights
March 14, 2024 | 2:00 pm
Portfolio Pulse from Bibhu Pattnaik
March 03, 2024 | 7:57 pm
Portfolio Pulse from Benzinga Insights
February 23, 2024 | 4:00 pm
Portfolio Pulse from Benzinga Insights
February 13, 2024 | 1:15 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.